Update Reimbursement Scheme Adempas®
As off May 31st 2023, the reimbursement for Adempas® 0.5 mg and 1.0 mg is now also indicated for the treatment of PAH in pediatric patients aged less than 18 years of age and body weight ≥ 50 kg with WHO Functional Class (FC) II to III in combination with endothelin receptor antagonists.
For more information check out the Adempas® 0.5 mg and 1.0 mg medicine page